Press Releases

 
Press Releases
Date Title and Summary View
Jan 25, 2018 SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, February 6, 2018.  During the call, Mark C. Capone, president and CEO and Bryan Riggsbee...
Jan 22, 2018 SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a new consensus statement from a team of international experts with screening recommendations on hereditary prostate cancer that was published in ...
Jan 12, 2018 SALT LAKE CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx® for use as a companion diagnostic by healthcare professionals to identify patients with HER2-negat...
Jan 3, 2018 SALT LAKE CITY, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company's myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit f...
Dec 19, 2017 SALT LAKE CITY, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual Healthcare Conference at 2:00 p.m. PT on January 8, 2018, in San Francisco...
Dec 12, 2017 SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Dec 8, 2017 SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Dec 6, 2017 SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Nov 10, 2017 SALT LAKE CITY, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the Department of Veterans Affairs (VA) recently initiated a national, multi-center trial to evaluate the company's GeneSight® test to help improve health outcom...
Nov 9, 2017 SALT LAKE CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the Jefferies Healthcare Conference at 8:40 a.m. GMT on November 16, 2017, at the Waldorf Hilt...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase